Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Income from Continuing Operations (2022 - 2025)

Stoke Therapeutics has reported Income from Continuing Operations over the past 4 years, most recently at 57824000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 57824000.0 for Q4 2025, down 441.27% from a year ago — trailing twelve months through Dec 2025 was 6775000.0 (up 92.4% YoY), and the annual figure for FY2025 was 6834000.0, up 92.3%.
  • Income from Continuing Operations for Q4 2025 was 57824000.0 at Stoke Therapeutics, down from 38347000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for STOK hit a ceiling of 112879000.0 in Q1 2025 and a floor of 57824000.0 in Q4 2025.
  • Median Income from Continuing Operations over the past 4 years was 25696000.0 (2022), compared with a mean of 18878500.0.
  • Peak annual rise in Income from Continuing Operations hit 527.99% in 2025, while the deepest fall reached 441.27% in 2025.
  • Stoke Therapeutics' Income from Continuing Operations stood at 25697000.0 in 2022, then decreased by 5.07% to 26999000.0 in 2023, then soared by 60.43% to 10683000.0 in 2024, then crashed by 441.27% to 57824000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 57824000.0 (Q4 2025), 38347000.0 (Q3 2025), and 23483000.0 (Q2 2025) per Business Quant data.